Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome

C. A. Read, D. Clauw, C. Weir, A. T. Da Silva, P. Katz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We reviewed the pulmonary history, dyspnea ratings, and pulmonary function test results in 16 patients with L-tryptophan-induced eosinophilia myalgia syndrome to determine the correlation between reported pulmonary complaints and pulmonary function abnormalities. All patients reported pulmonary symptoms. Dyspnea, seen in 14 of 16 (87 percent) patients, was the most common symptom. The severity of dyspnea was graded by the baseline dyspnea index and the oxygen cost diagram. Pulmonary function testing including maximal static inspiratory and expiratory pressures were measured. The DCO was diminished in 12 of 16 (75 percent) patients. The MSIP was decreased in seven out of ten (70 percent) and the MSEP was decreased in nine out of ten (90 percent) of those patients tested. There was a statistically significant correlation between the severity of dyspnea as graded by the BDI and OCD, and the decrease in DCO. These results and a review of the literature of the pulmonary manifestations of EMS lead us to conclude that patients with EMS have a high prevalence of dyspnea, and it appears to be caused by both lung parenchymal involvement, as well as respiratory muscle weakness.

Original languageEnglish
Pages (from-to)1282-1286
Number of pages5
JournalChest
Volume101
Issue number5
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Eosinophilia-Myalgia Syndrome
Tryptophan
Dyspnea
Lung
Respiratory Muscles
Respiratory Function Tests
Muscle Weakness
History
Oxygen
Costs and Cost Analysis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Read, C. A., Clauw, D., Weir, C., Da Silva, A. T., & Katz, P. (1992). Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome. Chest, 101(5), 1282-1286.

Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome. / Read, C. A.; Clauw, D.; Weir, C.; Da Silva, A. T.; Katz, P.

In: Chest, Vol. 101, No. 5, 01.01.1992, p. 1282-1286.

Research output: Contribution to journalArticle

Read, CA, Clauw, D, Weir, C, Da Silva, AT & Katz, P 1992, 'Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome', Chest, vol. 101, no. 5, pp. 1282-1286.
Read CA, Clauw D, Weir C, Da Silva AT, Katz P. Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome. Chest. 1992 Jan 1;101(5):1282-1286.
Read, C. A. ; Clauw, D. ; Weir, C. ; Da Silva, A. T. ; Katz, P. / Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome. In: Chest. 1992 ; Vol. 101, No. 5. pp. 1282-1286.
@article{4bc86e7c70e645f993e7e987e062446f,
title = "Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome",
abstract = "We reviewed the pulmonary history, dyspnea ratings, and pulmonary function test results in 16 patients with L-tryptophan-induced eosinophilia myalgia syndrome to determine the correlation between reported pulmonary complaints and pulmonary function abnormalities. All patients reported pulmonary symptoms. Dyspnea, seen in 14 of 16 (87 percent) patients, was the most common symptom. The severity of dyspnea was graded by the baseline dyspnea index and the oxygen cost diagram. Pulmonary function testing including maximal static inspiratory and expiratory pressures were measured. The DCO was diminished in 12 of 16 (75 percent) patients. The MSIP was decreased in seven out of ten (70 percent) and the MSEP was decreased in nine out of ten (90 percent) of those patients tested. There was a statistically significant correlation between the severity of dyspnea as graded by the BDI and OCD, and the decrease in DCO. These results and a review of the literature of the pulmonary manifestations of EMS lead us to conclude that patients with EMS have a high prevalence of dyspnea, and it appears to be caused by both lung parenchymal involvement, as well as respiratory muscle weakness.",
author = "Read, {C. A.} and D. Clauw and C. Weir and {Da Silva}, {A. T.} and P. Katz",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "101",
pages = "1282--1286",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome

AU - Read, C. A.

AU - Clauw, D.

AU - Weir, C.

AU - Da Silva, A. T.

AU - Katz, P.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - We reviewed the pulmonary history, dyspnea ratings, and pulmonary function test results in 16 patients with L-tryptophan-induced eosinophilia myalgia syndrome to determine the correlation between reported pulmonary complaints and pulmonary function abnormalities. All patients reported pulmonary symptoms. Dyspnea, seen in 14 of 16 (87 percent) patients, was the most common symptom. The severity of dyspnea was graded by the baseline dyspnea index and the oxygen cost diagram. Pulmonary function testing including maximal static inspiratory and expiratory pressures were measured. The DCO was diminished in 12 of 16 (75 percent) patients. The MSIP was decreased in seven out of ten (70 percent) and the MSEP was decreased in nine out of ten (90 percent) of those patients tested. There was a statistically significant correlation between the severity of dyspnea as graded by the BDI and OCD, and the decrease in DCO. These results and a review of the literature of the pulmonary manifestations of EMS lead us to conclude that patients with EMS have a high prevalence of dyspnea, and it appears to be caused by both lung parenchymal involvement, as well as respiratory muscle weakness.

AB - We reviewed the pulmonary history, dyspnea ratings, and pulmonary function test results in 16 patients with L-tryptophan-induced eosinophilia myalgia syndrome to determine the correlation between reported pulmonary complaints and pulmonary function abnormalities. All patients reported pulmonary symptoms. Dyspnea, seen in 14 of 16 (87 percent) patients, was the most common symptom. The severity of dyspnea was graded by the baseline dyspnea index and the oxygen cost diagram. Pulmonary function testing including maximal static inspiratory and expiratory pressures were measured. The DCO was diminished in 12 of 16 (75 percent) patients. The MSIP was decreased in seven out of ten (70 percent) and the MSEP was decreased in nine out of ten (90 percent) of those patients tested. There was a statistically significant correlation between the severity of dyspnea as graded by the BDI and OCD, and the decrease in DCO. These results and a review of the literature of the pulmonary manifestations of EMS lead us to conclude that patients with EMS have a high prevalence of dyspnea, and it appears to be caused by both lung parenchymal involvement, as well as respiratory muscle weakness.

UR - http://www.scopus.com/inward/record.url?scp=0026753582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026753582&partnerID=8YFLogxK

M3 - Article

C2 - 1582285

AN - SCOPUS:0026753582

VL - 101

SP - 1282

EP - 1286

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -